Empagliflozin

Metabolic

Glucose lowering and cardio-renal benefits

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Small molecule
Primary mechanism: SGLT2 inhibition
Primary market use: Diabetes/heart failure/CKD

Pharmacology

Molecular weight (Da): 450.9
Oral bioavailability: ~78%
Half-life: ~12.4 h
Route tags: Route-dependent / verify
Evidence level: Approved
Clinical status: Approved
Value-for-money score: 8 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Requires ongoing dosing

Sources

https://www.fda.gov/drugs